Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 71.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,605 shares of the specialty pharmaceutical company’s stock after buying an additional 4,835 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Jazz Pharmaceuticals were worth $2,687,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in JAZZ. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $768,000. Profund Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 208.0% during the third quarter. Profund Advisors LLC now owns 7,783 shares of the specialty pharmaceutical company’s stock worth $1,802,000 after acquiring an additional 5,256 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 4.1% during the third quarter. ProShare Advisors LLC now owns 4,718 shares of the specialty pharmaceutical company’s stock worth $1,092,000 after acquiring an additional 185 shares during the last quarter. Vise Technologies Inc. raised its position in shares of Jazz Pharmaceuticals by 5.3% during the third quarter. Vise Technologies Inc. now owns 2,448 shares of the specialty pharmaceutical company’s stock worth $567,000 after acquiring an additional 123 shares during the last quarter. Finally, State of Wyoming boosted its holdings in Jazz Pharmaceuticals by 191.3% in the third quarter. State of Wyoming now owns 2,534 shares of the specialty pharmaceutical company’s stock valued at $587,000 after acquiring an additional 1,664 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of several recent analyst reports. Canaccord Genuity Group set a $300.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, August 26th. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $337.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Piper Sandler lifted their price target on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $293.45.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the transaction, the executive vice president owned 47,671 shares of the company’s stock, valued at $11,485,850.74. The trade was a 2.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the sale, the executive vice president owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. The trade was a 53.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 102,534 shares of company stock valued at $25,185,243 in the last ninety days. Insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $234.76 on Friday. Jazz Pharmaceuticals PLC has a 1-year low of $128.80 and a 1-year high of $266.38. The stock has a market cap of $15.07 billion, a PE ratio of 79.85, a price-to-earnings-growth ratio of 0.44 and a beta of 0.38. The stock’s fifty day simple moving average is $229.39 and its two-hundred day simple moving average is $217.74. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.15. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.13 EPS. As a group, analysts forecast that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current fiscal year.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.